The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression
Open accessAbstract
We investigated whether TGF-beta induced by anticancer therapies accelerates tumor progression. Using the MMTV/PyVmT transgenic model of metastatic breast cancer, we show that administration of ionizing radiation or doxorubicin caused increased circulating levels of TGF-beta1 as well as increased circulating tumor cells and lung metastases. These effects were abrogated by administration of a neutralizing pan-TGF-beta antibody. Circulating polyomavirus middle T antigen-expressing tumor cells did not grow ex vivo in the presence of the TGF-beta antibody, suggesting autocrine TGF-beta is a survival signal in these cells. Radiation failed to enhance lung metastases in mice bearing tumors that lack the type II TGF-beta receptor, suggesting that the increase in metastases was due, at least in part, to a direct effect of TGF-beta on the cancer cells. These data implicate TGF-beta induced by anticancer therapy as a pro-metastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-beta inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Massagué, J., Seoane, J., & Wotton, D. (2005) · Genes & Development · doi:10.1101/gad.1350705 · Cited by 2,452
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Self-citationTGF-β signaling: positive and negative effects on tumorigenesis
Wakefield, L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00259-3 · Cited by 827
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Transforming growth factor-beta activation in irradiated murine mammary gland.
Barcellos-Hoff, M. H., Derynck, R., Tsang, M. L., & Weatherbee, J. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117045 · Cited by 431
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., & Massagué, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932636100 · Cited by 429
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
Self-citation(2000) · PubMed · Cited by 404
Metastasis is driven by sequential elevation of H-ras and Smad2 levels
Oft, M., Akhurst, R. J., & Balmain, A. (2002) · Nature Cell Biology · doi:10.1038/ncb807 · Cited by 373
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359
Self-citationYamaguchi, K., Takagi, Y., Aoki, S., Futamura, M., & Saji, S. (2000) · Annals of Surgery · doi:10.1097/00000658-200007000-00009 · Cited by 323
Anscher, M. S., Peters, W. P., Reisenbichler, H., Petros, W. P., & Jirtle, R. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306033282203 · Cited by 316
Conditional inactivation of the TGF‐β type II receptor using Cre:Lox
Chytil, A., Magnuson, M. A., Wright, C. V. E., & Moses, H. L. (2002) · genesis · doi:10.1002/gene.10046 · Cited by 269
Self-citationForrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A. E., Sharif-Afshar, A.-R., Muller, W. J., & Moses, H. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3272 · Cited by 249
Self-citationTargeting the TGFβ signaling network in human neoplasia
Dumont, N., & Arteaga, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00135-1 · Cited by 242
Self-citationType I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase
Yi, J. Y., Shin, I., & Arteaga, C. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413223200 · Cited by 228
Self-citationShariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 214
Muraoka, R. S., Koh, Y., Roebuck, L. R., Sanders, M. E., Brantley-Sieders, D., Gorska, A. E., Moses, H. L., & Arteaga, C. L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8691-8703.2003 · Cited by 191
Self-citationShin, I., Bakin, A. V., Rodeck, U., Brunet, A., & Arteaga, C. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.11.3328 · Cited by 178
Self-citationLucas, C., Bald, L. N., Fendly, B. M., Mora-Worms, M., Figari, I. S., Patzer, E. J., & Palladino, M. A. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.5.1415 · Cited by 164
Muraoka-Cook, R. S., Kurokawa, H., Koh, Y., Forbes, J. T., Roebuck, L. R., Barcellos-Hoff, M. H., Moody, S. E., Chodosh, L. A., & Arteaga, C. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2111 · Cited by 159
Self-citationTsushima, H., Ito, N., Tamura, S., Matsuda, Y., Inada, M., Yabuuchi, I., Imai, Y., Nagashima, R., Misawa, H., Takeda, H., et al. (2001) · PubMed · Cited by 149
The effect of surgical wounding on tumour development
Hofer, S. O. P., Molema, G., Hermens, R., Wanebo, H. J., Reichner, J. S., & Hoekstra, H. J. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1998.0634 · Cited by 149
Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Wojtowicz‐Praga, S. (2003) · Investigational New Drugs · doi:10.1023/a:1022951824806 · Cited by 146
Muraoka-Cook, R. S., Shin, I., Yi, J. Y., Easterly, E., Barcellos‐Hoff, M. H., Yingling, J. M., Zent, R., & Arteaga, C. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208964 · Cited by 139
Self-citationArteaga, C. L., Dugger, T. C., Moses, H. L., Hurd, S. D., & Pietenpol, J. A. (1993) · PubMed · Cited by 139
Self-citationShim, K. S., Kim, K. H., Han, W. S., & Park, E. B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<554::aid-cncr6>3.0.co;2-x · Cited by 138
The physical parameters and molecular events associated with radiation-induced lung toxicity
Vujašković, Ž., Marks, L. B., & Anscher, M. S. (2000) · Seminars in Radiation Oncology · doi:10.1053/srao.2000.9424 · Cited by 122
Anscher, M. S., Thrasher, B. A., Rabbani, Z. N., Teicher, B. A., & Vujašković, Ž. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.02.051 · Cited by 121
Inhibition of TGFβ signaling in cancer therapy
Arteaga, C. L. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.009 · Cited by 111
Self-citationJNK Regulates Autocrine Expression of TGF-β1
Ventura, J., Kennedy, N. J., Flavell, R. A., & Davis, R. J. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.007 · Cited by 96
Ito, N., Kawata, S., Tamura, S., Shirai, Y., Kiso, S., Tsushima, H., & Matsuzawa, Y. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)90156-6 · Cited by 96
Wang, S. E., Wu, F. Y., Shin, I., Qu, S., & Arteaga, C. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4703-4715.2005 · Cited by 83
Self-citationTian, F., Byfield, S. D., Parks, W. T., Stuelten, C. H., Nemani, D., Zhang, Y. E., & Roberts, A. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0030 · Cited by 82
The role of transforming growth factor-beta in primary brain tumors
Rich, J. N. (2003) · Frontiers in bioscience · doi:10.2741/992 · Cited by 76
Huang, Y. K., Hutter, D., Liu, Y., Wang, X., Sheikh, M. S., Chan, A. M.-L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909431199 · Cited by 64
Teicher, B. A., Ikebe, M., Ara, G., Keyes, S. R., & Herbst, R. S. (1997) · PubMed · Cited by 42
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215234 · Cited by 21
Self-citation
Cited by
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Metadata
- Authors
- Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1305-1313
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2118096781
- Cited by
- 346
- References
- 41
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.